Vaccitech plc (VACC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vaccitech plc (VACC) trades at $5.00 with AI Score 46/100 (Grade C). Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing novel T cell immunotherapeutics and vaccines. Market cap: $193M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VACC: VACC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VACC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VACC: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Vaccitech plc (VACC) Healthcare & Pipeline Overview
Vaccitech plc, founded in 2016, is a clinical-stage biopharmaceutical company developing T cell immunotherapeutics and vaccines for infectious diseases and cancers. With programs in various clinical trial phases, Vaccitech aims to address unmet needs in areas like hepatitis B, HPV, prostate cancer, and non-small cell lung cancer, positioning itself within the competitive biotechnology landscape.
What Is the Investment Thesis for VACC?
Vaccitech's investment thesis centers on its innovative T cell immunotherapy platform and diverse pipeline targeting significant unmet medical needs. The company's programs in Phase 1/2 clinical trials, including VTP-300 for chronic hepatitis B and VTP-200 for HPV, represent near-term value drivers. Successful clinical trial outcomes and potential partnerships could significantly boost the company's market capitalization, which currently stands at $0.19 billion. Key catalysts include data readouts from ongoing clinical trials and potential regulatory advancements. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The negative P/E ratio of -0.38 reflects the company's current investment in R&D and clinical development.
Based on FMP financials and quantitative analysis
VACC Key Highlights
Market capitalization of $193M reflects investor valuation of Vaccitech's pipeline and technology.
- Negative P/E ratio of -0.38 indicates the company is currently prioritizing R&D and clinical development over profitability.
- VTP-300, a lead therapeutic program for chronic hepatitis B infection, is in Phase 1/2a clinical trials, representing a near-term value driver.
- Vaxzevria, a COVID-19 vaccine, contributes to the company's revenue stream and validates its vaccine development capabilities.
- The company's pipeline includes both therapeutic and prophylactic programs, diversifying its risk and potential revenue streams.
Who Are VACC's Competitors?
VACC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRGX CARGO Therapeutics, Inc. Common Stock | $4.47 | +0.00% | $216M | 45 |
| FSTX F-star Therapeutics, Inc. | $7.12 | +0.00% | $157M | 65 |
| LENZ LENZ Therapeutics, Inc. | $4.66 | -5.28% | $146M | — |
| LSB LakeShore Biopharma Co., Ltd | $0.63 | +0.00% | $25.8M | 46 |
| SELB Selecta Biosciences | $0.88 | -8.00% | $135M | 46 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VACC's Key Strengths?
Proprietary T cell immunotherapy platform.
- Diverse pipeline targeting infectious diseases and cancers.
- Experienced management team.
- Strategic partnerships.
What Are VACC's Weaknesses?
Clinical-stage company with no approved products.
- Reliance on clinical trial success.
- High R&D expenses.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive VACC Stock Higher?
Data readouts from Phase 1/2a clinical trials for VTP-300 in chronic hepatitis B infection.
- Data readouts from Phase 1/2a clinical trials for VTP-200 in human papilloma virus (HPV) infection.
- Progression of VTP-850 into later-stage clinical trials for prostate cancer.
- Strategic partnerships and collaborations to expand the company's reach and accelerate development.
- Regulatory advancements and potential breakthrough therapy designations.
What Are the Key Risks for VACC?
Financial-distress signal — its Altman Z-Score of -0.67 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-59.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures and setbacks.
- Regulatory hurdles and delays in approvals.
- Competition from established pharmaceutical companies.
- High R&D expenses and potential need for additional funding.
- Intellectual property challenges and patent disputes.
What Are the Growth Opportunities for VACC?
- VTP-300 for Chronic Hepatitis B: The global market for hepatitis B treatment is substantial, with millions of people chronically infected. VTP-300, currently in Phase 1/2a clinical trials, represents a significant growth opportunity for Vaccitech. Positive clinical trial data could lead to partnerships and eventual commercialization, capturing a portion of this market. The timeline for potential market entry is dependent on successful trial outcomes and regulatory approvals, potentially within the next 3-5 years.
- VTP-200 for Human Papilloma Virus (HPV): HPV infection is a widespread concern, with several strains linked to cancers. VTP-200, in Phase 1/2a clinical trials, targets HPV infection and related diseases. Success in clinical trials could open up a significant market opportunity, addressing unmet needs in HPV treatment. The timeline for potential commercialization hinges on trial results and regulatory pathways, estimated within 4-6 years.
- VTP-850 for Prostate Cancer: Prostate cancer is a leading cause of cancer-related deaths in men. VTP-850, in Phase 1/2 clinical trials, aims to treat prostate cancer using T cell immunotherapy. Positive clinical outcomes could position Vaccitech as a key player in the prostate cancer treatment market. Commercialization timelines depend on clinical trial success and regulatory approvals, projected within 5-7 years.
- VTP-600 for Non-Small Cell Lung Cancer: Non-small cell lung cancer (NSCLC) is a prevalent and aggressive form of lung cancer. VTP-600, in Phase 1/2a clinical trials, targets NSCLC using T cell immunotherapy. Successful clinical development could provide a significant growth opportunity for Vaccitech in the oncology market. The timeline for potential market entry is contingent on trial data and regulatory processes, potentially within 6-8 years.
- VTP-400 for Herpes Zoster (Shingles) Prevention: Herpes zoster, or shingles, affects a significant portion of the aging population. VTP-400, currently in the preclinical stage, aims to prevent shingles. Successful development and clinical trials could lead to a substantial market opportunity in preventative medicine. The timeline for potential commercialization is longer, given the preclinical stage, estimated within 7-9 years.
What Opportunities Does VACC Have?
- Successful clinical trial outcomes.
- Regulatory approvals for lead programs.
- Expansion of pipeline through new targets and technologies.
- Strategic partnerships and collaborations.
What Are VACC's Competitive Advantages?
- Proprietary T cell immunotherapy platform.
- Strong intellectual property portfolio protecting their technologies.
- Experienced management team with expertise in vaccine and immunotherapy development.
- Strategic partnerships with leading research institutions and pharmaceutical companies.
What Does VACC Do?
Vaccitech plc, established in 2016 and headquartered in Oxford, UK, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel T cell immunotherapeutics and vaccines. The company's foundation lies in pioneering research around the activation and harnessing of T cells to combat various diseases. Vaccitech's portfolio encompasses both therapeutic and prophylactic programs, targeting infectious diseases and cancers. Key therapeutic programs include VTP-300 for chronic hepatitis B infection, currently in Phase 1/2a clinical trials; VTP-200 for human papilloma virus (HPV) infection, also in Phase 1/2a trials; VTP-850 for prostate cancer, undergoing Phase 1/2 clinical trials; and VTP-600 for non-small cell lung cancer, in Phase 1/2a trials. Prophylactic programs feature VTP-400 for the prevention of herpes zoster (shingles), in the preclinical stage; VTP-500 for the prevention of Middle East respiratory syndrome (MERS), which has completed Phase 1 clinical trials; and Vaxzevria, a COVID-19 vaccine. Vaccitech was formerly known as Vaccitech Rx Limited, changing its name to Vaccitech plc in March 2021. The company operates with 33 employees, focusing on advancing its pipeline through clinical development and strategic partnerships.
What Products and Services Does VACC Offer?
- Develop novel T cell immunotherapeutics and vaccines.
- Target infectious diseases such as chronic hepatitis B and HPV.
- Develop cancer immunotherapies for prostate and non-small cell lung cancer.
- Conduct preclinical and clinical trials to evaluate the safety and efficacy of their products.
- Seek partnerships with pharmaceutical companies for further development and commercialization.
- Focus on harnessing the power of T cells to combat diseases.
- Pioneer research in the field of T cell activation and immunotherapy.
How Does VACC Make Money?
- Develop proprietary T cell immunotherapy platform.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through milestone payments and royalties from partnered programs.
- Secure funding through venture capital, public offerings, and grants.
What Industry Does VACC Operate In?
Vaccitech operates within the competitive biotechnology industry, characterized by high R&D spending, lengthy clinical trial processes, and stringent regulatory requirements. The industry is driven by the increasing prevalence of infectious diseases and cancers, creating a demand for novel therapeutics and vaccines. Vaccitech's T cell immunotherapy platform positions it within the innovative segment of the market, competing with companies developing similar technologies. The biotechnology industry is experiencing growth, fueled by advancements in genomics, proteomics, and personalized medicine. Vaccitech's success depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy.
Who Are VACC's Key Customers?
- Pharmaceutical companies seeking novel therapeutics and vaccines.
- Patients suffering from infectious diseases and cancers.
- Healthcare providers administering vaccines and immunotherapies.
- Research institutions collaborating on clinical trials.
How Vaccitech plc Is Valued
Vaccitech plc carries a market capitalization of $193M, placing it in the micro-cap category. Relative to its peer group, VACC's quantitative score of 46/100 is roughly in line with the peer average of 51/100.
Company Profile
Vaccitech plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Oxford, GB. The company is led by CEO William J. Enright MBA. VACC has traded publicly since 2021.
Key Financial Metrics
Return on equity for Vaccitech plc stands at -59.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -51.0%, showing how much profit it generates from its asset base. A current ratio of 5.54 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -159.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Vaccitech plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.67 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Vaccitech plc has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 72.4% above estimates on average.
VACC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary T cell immunotherapy platform.
- Diverse pipeline targeting infectious diseases and cancers.
- Experienced management team.
- Strategic partnerships.
Bear Case
- Clinical-stage company with no approved products.
- Reliance on clinical trial success.
- High R&D expenses.
- Limited financial resources compared to larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
VACC Latest News
No recent news available for VACC.
VACC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VACC.
Price Targets
Wall Street price target analysis for VACC.
VACC MoonshotScore
What does this score mean?
The MoonshotScore rates VACC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: William J. Enright MBA
Chief Executive Officer
William J. Enright is the Chief Executive Officer of Vaccitech plc. He brings extensive experience in the biopharmaceutical industry, with a background in strategic leadership, business development, and financial management. Enright holds an MBA and has a proven track record of driving growth and innovation in the healthcare sector. His previous roles include leadership positions at various biotechnology and pharmaceutical companies, where he oversaw the development and commercialization of novel therapies.
Track Record: Under William Enright's leadership, Vaccitech plc has focused on advancing its pipeline of T cell immunotherapeutics and vaccines through clinical development. Key milestones include the progression of VTP-300 and VTP-200 into Phase 1/2a clinical trials and the continued development of VTP-850 and VTP-600. Enright has also overseen strategic partnerships and collaborations to expand the company's reach and accelerate its growth.
Vaccitech plc ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company's stock, allowing U.S. investors to trade the shares on U.S. stock exchanges. Vaccitech plc (VACC) is traded as an ADR, meaning U.S. investors can purchase and sell shares of Vaccitech, which is based in the United Kingdom, without dealing with foreign exchanges or currencies directly. The ADR represents a specific number of Vaccitech's ordinary shares held by a depositary bank.
- Home Market Ticker: London Stock Exchange, United Kingdom
- ADR Level: 2
- ADR Ratio: 1:1
Vaccitech plc Healthcare Stock: Key Questions Answered
What does the AI Score mean for VACC?
VACC holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing novel T cell immunotherapeutics and vaccines. Their pipeline targets infectious diseases and cancers, with several …
What does Vaccitech plc do?
Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's pipeline includes programs targeting chronic hepatitis B, HPV, prostate cancer, non-small cell lung cancer, herpes zoster, and MERS.
What are the main risks for VACC?
The main risks for Vaccitech plc include clinical trial failures, regulatory hurdles, competition from established pharmaceutical companies, high R&D expenses, and intellectual property challenges. Clinical trial failures could significantly impact the company's pipeline and valuation. Regulatory delays or rejections could hinder the commercialization of its products. Competition from larger companies with greater resources poses a threat to market share.
What are the key factors to evaluate for VACC?
Vaccitech plc (VACC) holds an AI score of 46/100 (low). Vaccitech's investment thesis centers on its innovative T cell immunotherapy platform and diverse pipeline targeting significant unmet medical needs. Not financial advice.
How frequently does VACC data refresh on this page?
VACC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VACC's recent stock price performance?
Vaccitech plc (VACC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary T cell immunotherapy platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VACC overvalued or undervalued right now?
Vaccitech plc (VACC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VACC before investing?
Before investing in Vaccitech plc (VACC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VACC to a portfolio?
Key strength of Vaccitech plc (VACC): Proprietary T cell immunotherapy platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending and may provide further insights.
- Financial data is based on publicly available information.
- Clinical trial data is subject to change and uncertainty.